US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HELUS PHARMA INC

11.70

-0.2100-1.76%

Post-market: 11.700.00000.00%19:56 EDT

Volume:1.41M

Turnover:16.51M

Market Cap:854.80M

PE:-2.89

High:12.30

Open:12.30

Low:11.52

Close:11.91

52wk High:15.15

52wk Low:3.76

Shares:73.06M

Float Shares:57.28M

Volume Ratio:1.43

T/O Rate:2.46%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0491

EPS(LYR):-3.8923

ROE:-86.94%

ROA:-44.38%

PB:3.53

PE(LYR):-3.01

Loading ...

Overview Company News Filings

Cybin Changes Legal Name to Helus Pharma

MT Newswires Live

Canaccord Genuity Keeps Their Buy Rating on Helus Pharma (HELP)

H.C. Wainwright Remains a Buy on Helus Pharma (HELP)

Helus Pharma presents new analyses on HLP003 in MDD

Helus Pharma : Barclays Initiates Coverage with Overweight Rating; Target Price $35

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Helus Pharma (HELP)

Cybin (HELP) Shares Just Moved, So What Is Behind The Attention?

Simply Wall St.

Cybin (HELP) Is Up 19.8% After Deepening Psychedelic Pipeline And Leadership Shift Is The Risk Story Changing?

Simply Wall St.

OB Holdings Signs MoU with HELP University to Build Entrepreneurship Platform

MT Newswires Live

Cybin Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate

Benzinga Earnings

ASTROTECH APPOINTS STRATEGIC ADVISORY BOARD TO HELP ADVANCE LUNAR RESOURCES AND INFRASTRUCTURE INITIATIVE

Cybin Inc. Expected to Post a Loss of C$1.17 a Share - Earnings Preview

Helus Pharma Shares Rise After Appointing New CEO

MT Newswires Live

Helus Pharma appoints Michael Halstead as CEO

Helus Pharma Names Michael Halstead CEO

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

Helus Pharma Completes Enrollment in Phase 3 Study for Depression Treatment

MT Newswires Live

Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003

Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/HELP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELP\",,,,,undefined,":{"symbol":"HELP","market":"US","secType":"STK","nameCN":"HELUS PHARMA INC","latestPrice":11.7,"timestamp":1790971200000,"preClose":11.91,"halted":0,"volume":1407756,"hourTrading":{"tag":"盘后","latestPrice":11.7,"preClose":11.7,"latestTime":"19:56 EDT","volume":7693,"amount":90055.8462,"timestamp":1790985406820,"change":0,"changeRate":0,"amplitude":0.022222},"delay":0,"changeRate":-0.017632241813602085,"floatShares":57284091,"shares":73060200,"eps":-4.049081,"marketStatus":"Market Closed","change":-0.21,"latestTime":"10-02 16:00:00 EDT","open":12.295,"high":12.295,"low":11.52,"amount":16514765.730120001,"amplitude":0.065071,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.049081,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":11.91,"preHourTrading":{"tag":"盘前","latestPrice":12.08,"preClose":11.91,"latestTime":"09:25 EDT","volume":9942,"amount":121328.78772,"timestamp":1790947500054,"change":0.17,"changeRate":0.014274,"amplitude":0.025189},"postHourTrading":{"tag":"盘后","latestPrice":11.7,"preClose":11.7,"latestTime":"19:56 EDT","volume":7693,"amount":90055.8462,"timestamp":1790985406820,"change":0,"changeRate":0,"amplitude":0.022222},"volumeRatio":1.431589386306582,"impliedVol":1.7543,"impliedVolPercentile":0.7021},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELP\",,,,,undefined,":{"symbol":"HELP","floatShares":57284091,"roa":"-44.38%","roe":"-86.94%","lyrEps":-3.892309,"volumeRatio":1.431589386306582,"shares":73060200,"dividePrice":0,"high":12.295,"amplitude":0.065071,"preClose":11.91,"low":11.52,"week52Low":3.76,"pbRate":"3.53","week52High":15.15,"institutionHeld":0,"latestPrice":11.7,"eps":-4.049081,"divideRate":0,"volume":1407756,"delay":0,"ttmEps":-4.049081,"open":12.295,"prevYearClose":8.18,"prevWeekClose":12.61,"prevMonthClose":12.29,"prevQuarterClose":12.29,"fiveDayClose":12.61,"twentyDayClose":11.77,"sixtyDayClose":6.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"HELP","fiscalQuarterEnding":"2026/06","expectedEps":-0.8,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.91},{"market":"US","date":"2026-06-29","symbol":"HELP","fiscalQuarterEnding":"2026/03","expectedEps":-1.04,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1782705600000,"reportTimeType":"pre","actualEps":-1.02},{"market":"US","date":"2026-02-13","symbol":"HELP","fiscalQuarterEnding":"2025/12","expectedEps":-0.53,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1770958800000,"reportTimeType":"pre","actualEps":-0.72}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.8182,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8182,"analysts":11,"updateTime":1789790400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HELP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HELP","date":"2026-10-02","current":-2.889545,"percent":0.135135,"low":-5.982942,"twenty":-4.44425,"median":-2.841674,"eighty":-1.969476,"high":-1.57152,"avg":-3.217821,"sd":1.308326,"marketCap":870146648},"quantilePoints":[{"date":"2026-01-09","current":-4.237274,"twenty":-4.344211,"median":-4.257397,"eighty":-4.216576,"marketCap":367789729},{"date":"2026-01-16","current":-4.513243,"twenty":-4.471847,"median":-4.329263,"eighty":-4.240723,"marketCap":391743470},{"date":"2026-01-23","current":-4.432752,"twenty":-4.4477,"median":-4.415504,"eighty":-4.256821,"marketCap":384756963},{"date":"2026-01-30","current":-3.892312,"twenty":-4.44425,"median":-4.332138,"eighty":-4.197028,"marketCap":337847553},{"date":"2026-02-06","current":-3.369121,"twenty":-4.439651,"median":-4.243023,"eighty":-3.91531,"marketCap":292435253},{"date":"2026-02-13","current":-3.403617,"twenty":-4.425853,"median":-4.199903,"eighty":-3.703734,"marketCap":295429471},{"date":"2026-02-20","current":-2.801935,"twenty":-4.400556,"median":-4.133785,"eighty":-3.477209,"marketCap":345246985},{"date":"2026-02-27","current":-3.151162,"twenty":-4.339612,"median":-3.892312,"eighty":-3.128422,"marketCap":388277769},{"date":"2026-03-06","current":-2.290278,"twenty":-4.333863,"median":-3.768701,"eighty":-3.012284,"marketCap":282201883},{"date":"2026-03-13","current":-2.083178,"twenty":-4.318914,"median":-3.656589,"eighty":-2.772698,"marketCap":256683628},{"date":"2026-03-20","current":-1.953233,"twenty":-4.27062,"median":-3.450978,"eighty":-2.359311,"marketCap":240672173},{"date":"2026-03-27","current":-1.888261,"twenty":-4.241873,"median":-3.369121,"eighty":-2.142465,"marketCap":232666446},{"date":"2026-04-02","current":-2.026327,"twenty":-4.237274,"median":-3.151162,"eighty":-1.973537,"marketCap":249678617},{"date":"2026-04-10","current":-2.127847,"twenty":-4.214276,"median":-3.041521,"eighty":-2.026327,"marketCap":262187565},{"date":"2026-04-17","current":-2.233427,"twenty":-4.185529,"median":-2.883151,"eighty":-2.079117,"marketCap":275196872},{"date":"2026-04-24","current":-2.334946,"twenty":-4.168281,"median":-2.755237,"eighty":-2.079117,"marketCap":287705821},{"date":"2026-05-01","current":-2.156272,"twenty":-4.099289,"median":-2.473013,"eighty":-2.079117,"marketCap":265690071},{"date":"2026-05-08","current":-2.168454,"twenty":-3.949806,"median":-2.332915,"eighty":-2.083178,"marketCap":267191145},{"date":"2026-05-15","current":-2.054753,"twenty":-3.892312,"median":-2.278095,"eighty":-2.070996,"marketCap":253181122},{"date":"2026-05-22","current":-1.867957,"twenty":-3.817571,"median":-2.245609,"eighty":-2.001963,"marketCap":230164657},{"date":"2026-05-29","current":-1.823288,"twenty":-3.808372,"median":-2.233427,"eighty":-1.952421,"marketCap":224660719},{"date":"2026-06-05","current":-1.798924,"twenty":-3.746279,"median":-2.217184,"eighty":-1.904504,"marketCap":221658571},{"date":"2026-06-12","current":-1.644614,"twenty":-3.694535,"median":-2.188759,"eighty":-1.887449,"marketCap":202644969},{"date":"2026-06-18","current":-1.859835,"twenty":-3.668088,"median":-2.162363,"eighty":-1.864708,"marketCap":229163941},{"date":"2026-06-26","current":-2.444587,"twenty":-3.642791,"median":-2.156272,"eighty":-1.87283,"marketCap":301215485},{"date":"2026-07-02","current":-2.630171,"twenty":-3.565692,"median":-2.168454,"eighty":-1.879327,"marketCap":389260009},{"date":"2026-07-10","current":-2.776757,"twenty":-3.45355,"median":-2.19891,"eighty":-1.885824,"marketCap":410954437},{"date":"2026-07-17","current":-2.948472,"twenty":-3.424315,"median":-2.233427,"eighty":-1.891509,"marketCap":436367909},{"date":"2026-07-24","current":-3.237455,"twenty":-3.399137,"median":-2.237487,"eighty":-1.896382,"marketCap":479136922},{"date":"2026-07-31","current":-3.40917,"twenty":-3.401377,"median":-2.263883,"eighty":-1.897194,"marketCap":504550394},{"date":"2026-08-07","current":-4.648869,"twenty":-3.432324,"median":-2.290278,"eighty":-1.901255,"marketCap":688023265},{"date":"2026-08-14","current":-4.795455,"twenty":-3.679587,"median":-2.339007,"eighty":-1.904504,"marketCap":709717693},{"date":"2026-08-21","current":-4.514739,"twenty":-3.872812,"median":-2.466832,"eighty":-1.909377,"marketCap":772941452},{"date":"2026-08-28","current":-5.650082,"twenty":-4.154483,"median":-2.567348,"eighty":-1.928869,"marketCap":967316677},{"date":"2026-09-04","current":-5.022769,"twenty":-4.209892,"median":-2.630171,"eighty":-1.93293,"marketCap":859918224},{"date":"2026-09-11","current":-5.479385,"twenty":-4.237274,"median":-2.732902,"eighty":-1.949173,"marketCap":938092608},{"date":"2026-09-18","current":-5.982942,"twenty":-4.329263,"median":-2.766884,"eighty":-1.953233,"marketCap":1024303611},{"date":"2026-09-25","current":-5.372699,"twenty":-4.410143,"median":-2.797698,"eighty":-1.969476,"marketCap":919827565},{"date":"2026-10-02","current":-5.082514,"twenty":-4.44425,"median":-2.841674,"eighty":-1.969476,"marketCap":870146648}],"updateTime":1791070451559},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672757261","title":"Cybin Changes Legal Name to Helus Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757261","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757261?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:08","pubTimestamp":1790860135,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) has changed its legal name from Cybin to Helus Pharma, effective immediately, the company said Thursday.Shareholders approved the name change last month following the adoption of t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488337","title":"Canaccord Genuity Keeps Their Buy Rating on Helus Pharma (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488337","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669488337?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:16","pubTimestamp":1790162167,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Helus Pharma today and set a price target of $42.00. According to TipRanks, Ku...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-keeps-their-buy-rating-on-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-keeps-their-buy-rating-on-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669614339","title":"H.C. Wainwright Remains a Buy on Helus Pharma (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669614339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669614339?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:45","pubTimestamp":1790070346,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Helus Pharma, with a price target of $70.00. Trucc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669684191","title":"Helus Pharma presents new analyses on HLP003 in MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669684191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669684191?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:35","pubTimestamp":1789990521,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) announced the presentation of four posters evaluating HLP003 at Psych Congress 2026, September 15-19, 2026, at the Ernest Moria...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-presents-new-analyses-on-hlp003-in-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-presents-new-analyses-on-hlp003-in-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP","ABVC","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669152334","title":"Helus Pharma : Barclays Initiates Coverage with Overweight Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2669152334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669152334?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:58","pubTimestamp":1789984715,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664583470","title":"Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Helus Pharma (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664583470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664583470?lang=en_us&edition=fundamental","pubTime":"2026-09-01 16:30","pubTimestamp":1788251407,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Capricor Therapeutics (CAPR) and Helus Pharma (HELP)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-capricor-therapeutics-capr-and-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-capricor-therapeutics-capr-and-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HELP","BK4007","BK4139","XLV","LU0029874061.USD","BK4585","CAPR","HCSG","XBI","BK4137","LABU","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663927960","title":"Cybin (HELP) Shares Just Moved, So What Is Behind The Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663927960","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663927960?lang=en_us&edition=fundamental","pubTime":"2026-08-28 23:29","pubTimestamp":1787930998,"startTime":"0","endTime":"0","summary":"Cybin (HELP) has moved into focus after advancing its lead psychedelic therapy HLP003 into a Phase 3 trial for major depressive disorder, alongside leadership changes including the appointment of Michael Halstead as CEO.\nCybin’s recent progress on HLP003 and leadership hires has come alongside sharp share price swings, with a 30 day share price return of 74.21% and a 90 day share price return of 190.99%. Over a 1 year period the total shareholder return is 73.30%, but the 5 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-shares-just-moved-so-what-is-behind-the-attention","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-shares-just-moved-so-what-is-behind-the-attention","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744784","title":"Cybin (HELP) Is Up 19.8% After Deepening Psychedelic Pipeline And Leadership Shift Is The Risk Story Changing?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744784","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662744784?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:31","pubTimestamp":1787772662,"startTime":"0","endTime":"0","summary":"In August 2026, Cybin Inc. reported a first-quarter net loss of US$47.82 million, with basic and diluted loss per share from continuing operations of US$0.91, while Helus Pharma appointed experienced HR leader Regina Donohue as Chief People Officer and CNS drug-development expert Suresh Durgam, M.D., to its Scientific Advisory Board.\nInvestor interest in Cybin has been influenced by its psychedelic medicine pipeline progress, including HLP003 entering a Phase 3 trial for major depressive...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-is-up-198-after-deepening-psychedelic-pipeline-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-is-up-198-after-deepening-psychedelic-pipeline-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHAT","AIPO","BK4007","AGIX","HELP","VTHR","ARTY","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660110264","title":"OB Holdings Signs MoU with HELP University to Build Entrepreneurship Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2660110264","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660110264?lang=en_us&edition=fundamental","pubTime":"2026-08-19 12:36","pubTimestamp":1787114175,"startTime":"0","endTime":"0","summary":"OB Holdings  signed a memorandum of understanding with HELP University to jointly develop an AI entrepreneurship platform and create similar opportunities, according to a Tuesday filing with Bursa Malaysia.The fortified food and dietary supplements maker aims to speed up the commercialization of AI innovations, build talent and practical skills and improve employability through the partnership.In the second phase of the partnership, the company may host student internships at its high-tech manufacturing facility.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGSX","HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659441831","title":"Cybin Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659441831","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659441831?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:15","pubTimestamp":1786713350,"startTime":"0","endTime":"0","summary":"Cybin Inc. reports results for the quarter ended June 30 - Earnings SummaryCybin Inc.HELP.NLBreported a quarterly adjusted loss of C$1.26 per share for the quarter ended June 30, higher than the same ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146118","title":"Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146118","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146118?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:53","pubTimestamp":1786708407,"startTime":"0","endTime":"0","summary":"Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.07) by 14.95 percent. This is a 17.27 percent increase over losses of $(1.10) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61205038/helus-pharma-q1-eps-0-91-beats-1-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908918","title":"ASTROTECH APPOINTS STRATEGIC ADVISORY BOARD TO HELP ADVANCE LUNAR RESOURCES AND INFRASTRUCTURE INITIATIVE","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908918","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908918?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:15","pubTimestamp":1786540500,"startTime":"0","endTime":"0","summary":"Advisors will support Astrotech's planned proposal under NASA's upcoming final NextSTEP-3 Appendix A solicitation and bring experience in space systems, lunar science, autonomous mining, artificial in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343754/0/en/astrotech-appoints-strategic-advisory-board-to-help-advance-lunar-resources-and-infrastructure-initiative.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UFO","XT","BK4544","HELP","ARKX","BK4007","BK4564","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610463","title":"Cybin Inc. Expected to Post a Loss of C$1.17 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610463","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610463?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:14","pubTimestamp":1786101247,"startTime":"0","endTime":"0","summary":"Cybin Inc. <HELP.NLB> expected to post a loss of C$1.17 a share - Earnings PreviewCybin Inc.HELP.NLBis expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4440Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657255025","title":"Helus Pharma Shares Rise After Appointing New CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657255025","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657255025?lang=en_us&edition=fundamental","pubTime":"2026-08-05 22:54","pubTimestamp":1785941658,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) shares rose 5% on Wednesday after the company said it appointed Michael Halstead as chief executive officer, effective immediately.Halstead was most recently the president of Intra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657152341","title":"Helus Pharma appoints Michael Halstead as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657152341","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657152341?lang=en_us&edition=fundamental","pubTime":"2026-08-05 22:38","pubTimestamp":1785940721,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) announced Monday the appointment of Michael Halstead as CEO. Halstead brings 25 years of industry experience, most recently ser...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-appoints-michael-halstead-as-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-appoints-michael-halstead-as-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656371843","title":"Helus Pharma Names Michael Halstead CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2656371843","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656371843?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:45","pubTimestamp":1785761102,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) appointed Michael Halstead as chief executive officer, effective immediately, the company said Monday.Halstead previously served as president of Intra-Cellular Therapies, the company said.Shares of the company were up 2.2% in Monday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653719909","title":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653719909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653719909?lang=en_us&edition=fundamental","pubTime":"2026-07-23 13:50","pubTimestamp":1784785838,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nek...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-helus-pharma-help-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-helus-pharma-help-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","LU0345769631.USD","JDOC","LU0882574055.USD","LU0820561909.HKD","IXJ","LU1032955483.USD","LABU","NKTR","LU1718418525.SGD","HELP","LU0029874061.USD","LU0234572021.USD","LU0053666078.USD","LU0689626769.HKD","IE00BGHQF631.EUR","XBI","LU1629891620.HKD","LU0787776722.HKD","IE000BZT7R73.USD","XLV","IE00B3PB1722.GBP","MEDX","GDOC","PJP","LU1244550221.USD","LU2602419157.SGD","LU0162691827.USD","IYH","IE000MB6IJN5.SGD","LU0683600562.USD","TRUH","FHLC","IHE","IE00B42XCP33.USD","LU0124676726.USD","IE00BSNM7G36.USD","FTXH","BK4532","SGXZ57979304.SGD","LU1674673691.USD","JNJ","LU1162221912.USD","HCSG","RXL","VHT","LU1196500208.SGD","LU0210536198.USD","LU1074936037.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653016762","title":"Helus Pharma Completes Enrollment in Phase 3 Study for Depression Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2653016762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653016762?lang=en_us&edition=fundamental","pubTime":"2026-07-22 00:06","pubTimestamp":1784649966,"startTime":"0","endTime":"0","summary":"Helus Pharma  said Tuesday it has completed enrollment in its phase 3 study of HLP003 in patients living with major depressive disorder.The trial enrolled 223 adults with moderate to severe major depressive disorder who experience an inadequate response despite a stable antidepressant regimen, the company said.The pharmaceutical company expects to release topline data in Q4 and targets a potential new drug application with the US Food and Drug Administration in 2028, it added.Enrollment is continuing in the program's second pivotal study, and eligible participants can roll over into a long-term extension trial to further evaluate safety, Helus Pharma said.Shares of the company were up nearly 16% in Tuesday trading.Price: 8.33, Change: +1.22, Percent Change: +17.16","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653060422","title":"Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003","url":"https://stock-news.laohu8.com/highlight/detail?id=2653060422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653060422?lang=en_us&edition=fundamental","pubTime":"2026-07-21 23:05","pubTimestamp":1784646331,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder. APP...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652218051","title":"Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218051","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218051?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:17","pubTimestamp":1784542665,"startTime":"0","endTime":"0","summary":"We'd be surprised if Cybin Inc. ( NASDAQ:HELP ) shareholders haven't noticed that the Chief Financial Officer, Greg...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/chief-financial-officer-greg-cavers-sold-a-bunch-of-shares-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/chief-financial-officer-greg-cavers-sold-a-bunch-of-shares-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}